Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup Analyses

Long-term treatment with linvoseltamab 200 mg provided deep and durable responses, with no new safety signals, and thus represents an effective therapeutic option in RRMM.

Authors

Institutions

Publication Details

Journal
Clinical Lymphoma Myeloma & Leukemia
Published
2025-11-15
DOI
https://doi.org/10.1016/j.clml.2025.11.004
Citations
3
Primary Topic
Multiple Myeloma Research and Treatments
Type
article
Field-Weighted Citation Impact
5.31

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup Analyses

Michelle DeVeaux, Mansi R. Shah, Karen Rodriguez Lorenc, Ja Min Byun et al.
3 citations
Clinical Lymphoma Myeloma & Leukemia
Multiple Myeloma Research and Treatments
5.31
article

Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup Analyses

Michelle DeVeaux, Mansi R. Shah, Karen Rodriguez Lorenc, Ja Min Byun, Matthew J. Pianko, Naresh Bumma, Rebecca Silbermann, Sundar Jagannath, Joshua Ryan Richter, Suzanne Lentzsch, Megan Seraphin, Joaquín Martínez‐López, Jeffrey A. Zonder, Marie‐Christiane Vekemans, Markus Munder, Ka Lung Wu, Jing Christine Ye, Anita Boyapati, Hans Chulhee Lee, Attaya Suvannasankha, Glenn Scott Kroog, Katherine L. B. Knorr, Rachid Baz, Tito Roccia, Dhruti Chokshi, Madhav V. Dhodapkar, James E. Hoffman, Joseph Maly, Swathi Namburi, Anasuya Hazra, Chang‐Ki Min
article en
3 citations

Abstract

Long-term treatment with linvoseltamab 200 mg provided deep and durable responses, with no new safety signals, and thus represents an effective therapeutic option in RRMM.

Clinical Lymphoma Myeloma & LeukemiaVol. 26(2)
Rutgers, The State University of New Jersey (US), Indiana University Health (US), Cliniques Universitaires Saint-Luc (BE), The University of Texas MD Anderson Cancer Center (US), Emory University (US), Oregon Health & Science University (US), Regeneron (United States) (US), Johannes Gutenberg University Mainz (DE), Norton Healthcare (US), Columbia University Irving Medical Center (US), Seoul National University Hospital (KR), Moffitt Cancer Center (US), The Barbara Ann Karmanos Cancer Institute (US), Hospital Universitario 12 De Octubre (ES), University of Miami Health System (US), Klinik und Poliklinik für Psychosomatische Medizin und Psychotherapie (DE), Richard L. Roudebush VA Medical Center (US), Center for Cancer and Blood Disorders (US), Michigan Center for Translational Pathology (US), Ziekenhuisnetwerk Antwerpen Stuivenberg (BE), The Catholic University of Korea Seoul St. Mary's Hospital (KR), The Ohio State University (US), Indiana University – Purdue University Indianapolis (US), Icahn School of Medicine at Mount Sinai (US)
Regeneron Pharmaceuticals
Openalex Percentile: Top 4%
Multiple Myeloma Research and Treatments
5.31
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.